SCHEMBL7468522

SCHEMBL7468522

COc1ccccc1C(Br)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.53
POLB P06746 2/20 0.51
HTT P42858 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA7 P43166 3/20 0.47
CA9 Q16790 3/20 0.47
CA12 O43570 2/20 0.47
CA14 Q9ULX7 2/20 0.47
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CA4 P22748 1/20 0.44
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8933613 0.85 POLB (0.47) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL639945 0.83 POLB (0.46) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL7475532 0.83 CA1 (0.48) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL20299495 0.81 HTT (0.42) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL4628923 0.80 KMT2A (0.56) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL11383904 0.79 KMT2A (0.48) KMT2AL3MBTL1PTGS1PTGS2ALDH1A1
SCHEMBL6788195 0.79 POLB (0.48) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL8473051 0.78 PTGS2 (0.64) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL7885098 0.78 PTGS2 (0.64) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL6400516 0.78 KMT2A (0.55) KMT2APOLBHTTNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428432-B2 Thienopyrimidine derivatives having stereo configurations and use thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2025-09-30 US disclosed
CN-113924303-B Thienopyrimidine derivatives with steric configuration and application thereof in medicines 广东东阳光药业股份有限公司 2023-10-20 CN disclosed
EP-3571205-B1 THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-08-30 EP disclosed
CN-115160340-A Small molecule compound with ACK1 inhibitory activity and application thereof 四川大学华西医院 2022-10-11 CN disclosed
US-20220267346-A1 THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-08-25 US disclosed
EP-3995498-A1 THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINE Sunshine Lake Pharma Co., Ltd. (CN) 2022-05-11 EP disclosed
EP-3995498-A1 THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINE Sunshine Lake Pharma Co., Ltd. (CN) 2022-05-11 EP disclosed
CN-113924303-A Thienopyrimidine derivatives with spatial configuration and application thereof in medicines 广东东阳光药业有限公司 2022-01-11 CN disclosed
CN-108341830-B Thienopyrimidine derivatives and their use in medicine 广东东阳光药业有限公司 2021-03-02 CN disclosed
WO-2021000242-A1 THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINE 广东东阳光药业有限公司 2021-01-07 WO disclosed
WO-2021000242-A1 THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINE 广东东阳光药业有限公司 2021-01-07 WO disclosed
US-10759812-B2 Thienopyrimidine derivative and use thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-09-01 US disclosed
US-20190352311-A1 THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-11-21 US disclosed
CN-108341830-A Thienopyrimidine derivative and its application in drug 广东东阳光药业有限公司 2018-07-31 CN disclosed
EP-1077701-A4 ANTI-VIRAL COMPOUNDS LILLY CO ELI (US) 2002-03-20 EP disclosed
US-6358971-B1 FOR INHIBITING THE GROWTH OF A PICORNAVIRUS ELI LILLY AND COMPANY 2002-03-19 US disclosed
CN-1292697-A Anti-viral compound LILLY CO ELI (US) 2001-04-25 CN disclosed
EP-1077701-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 2001-02-28 EP disclosed
WO-1999059587-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 1999-11-25 WO disclosed
WO-1991011999-A1 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO., INC. (US) 1991-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267346-A1 THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINE ACACA, ACACB, ACAT2 KMT2A 2955/4885POLB 1091/4885HTT 2730/4885
US-20190352311-A1 THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE ACACA, ACACB, PC KMT2A 2582/4885POLB 1001/4885HTT 2214/4885
US-12428432-B2 Thienopyrimidine derivatives having stereo configurations and use thereof in medicine ACACA, ACACB, ACAT2 KMT2A 2955/4885POLB 1091/4885HTT 2730/4885
US-10759812-B2 Thienopyrimidine derivative and use thereof in medicine ACACA, ACACB, PC KMT2A 2582/4885POLB 1001/4885HTT 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.